PSMA PET Imaging and Theranostics in Prostate Cancer: Current Landscape and Future Directions

Posted by Jack R. Andrews, MD

Overview
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer cells and minimally on normal tissue, making it an ideal diagnostic and therapeutic target. While its biologic function remains unclear, its consistent overexpression enables both imaging (PET) and therapy (theranostics) applications.

1. PSMA PET Imaging in Staging and Biochemical Recurrence (BCR)

• Tracers: The three major FDA-approved tracers are Ga-68 PSMA-11 (Gallium GoPSMA), 18F-DCFPyL (Pylarify), and 18F-PSMA-1007 (Posluma).
• Performance: Across pivotal trials, PSMA PET shows higher specificity (94–98%) than sensitivity (23–40%)—it detects more true negatives but misses some small nodal metastases (<5 mm).
• Interpretation Tips:
  
  • Isolated rib lesions are usually benign (per BJUI study: 61/62 non-malignant).
  • PSMA PET outperforms conventional imaging but cannot yet replace lymph-node dissection in high-risk surgery.
  • NCCN recommends use mainly in unfavorable intermediate- and high-risk disease; not for low-risk (Gleason 3+3, 3+4).
• In Practice: High-risk patients are staged with PSMA PET; however, surgeons should still perform lymph-node dissection if previously indicated.

2. PSMA PET in BCR (Post-Prostatectomy)

• Detection Rates:
  
  • PSA < 0.2 ng/mL → < 30% positive
  • 0.2–0.5 ng/mL → 30–50% positive
  • Faster doubling time (< 6 mo) markedly increases positivity (~80%).
• Clinical Implication: Timing is critical—scans too early may be falsely negative and hard to repeat due to insurance restrictions.
• Natural History Context: Earlier detection alone (without altered therapy) may not change outcomes—management adaptation is key.

3. PSMA Theranostics (Lu-177-PSMA, α-Emitters, and Beyond)

• Lu-177-PSMA (Pluvicto): FDA-approved after the VISION trial showing ~4-month OS improvement in post-ARPI mCRPC.
• Ongoing Trials: Moving therapy earlier—LuTectomy, single arm neoadjuvant Lu-177 PSMA and the Nautilus Trial, neo-adjuvant Lu-177 PSMA trial randomized with/without ADT exploring synergy and safety.
• Next-Gen Strategies:
  
  • Alpha emitters (shorter wavelength, target micrometastases more effectively).
  • Bispecific PSMA immunotherapies aiming to “heat up” immunologically cold prostate tumors.
  • Copper-64 SAR-BisPSMA offers stronger binding and delayed imaging to enhance signal-to-noise ratio.
  • AI and liquid biomarkers may soon guide PSMA expression quantification and predict therapeutic response.

4. Key Takeaways

• PSMA PET has revolutionized prostate-cancer staging and recurrence detection, but small-node sensitivity limits full replacement of surgical staging.
• In BCR, PSA kinetics and timing determine imaging yield and utility.
• Theranostics now add a treatment dimension—offering targeted radiotherapy with measurable survival benefit.
• Future innovations lie in alpha-emitters, AI-driven quantification, and combined molecular-immunologic strategies that may finally personalize PSMA-based care.